Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127254) titled 'A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of Rolapitant Palonosetron for Injection in Preventing Nausea and Vomiting Induced by Antibody-Drug Conjugates, Using Fosaprepitant Dimeglumine for Injection Combined with Palonosetron Hydrochloride as the Active Control' on June 28.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Beijing Cancer Hospital

Condition: Nausea and vomiting in patients receiving ADC therapy for the first time

Intervention: Control group:HR20013 injection analog, fosaprepitan...